Fresenius Medical Care
AI Overview
With $1.7M in lobbying spend across 29 quarterly filings, Fresenius Medical Care is a significant lobbying presence. Their lobbying covers 1 issue area. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $240K |
| 2020 | $180K |
| 2021 | $180K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $240K |
| 2025 | $180K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments; CMS payment regulations impacting vascular access clinics and ASCs
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments; CMS shared savings plans
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; implementation of CARES Act; third party payments; access to Medicare Advantage plans for ESRD patients
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; implementation of CARES Act; vaccine distribution; extension of medicine sequester; telehealth policy and waivers
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; implementation of CARES Act; COVID vaccination policy; extension of medicine sequester; telehealth policy and waivers
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; implementation of CARES Act; COVID vaccination policy; extension of medicine sequester; telehealth policy and waivers; Provider Relief Fund
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; implementation of CARES Act; COVID vaccination policy; extension of medicine sequester; telehealth policy and waivers; Provider Relief Fund; issues pertaining to Medicare Secondary Payer Act
Showing 8 of 10 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.